Literature DB >> 24777030

The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells.

Qinqin Cheng1, Hongdong Shi, Hongxia Wang, Yuanzeng Min, Jun Wang, Yangzhong Liu.   

Abstract

Asplatin, a fusion of aspirin and cisplatin, exhibits significant cytotoxicity in tumor cells and almost fully overcomes the drug resistance of cisplatin resistant cells. Asplatin is highly accumulated in cancer cells and is activated upon the reduction by ascorbic acid.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24777030     DOI： 10.1039/c4cc00419a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  24 in total

1.  Mitochondria-Localized Fluorescent BODIPY-Platinum Conjugate.

Authors:  Tingting Sun; Xingang Guan; Min Zheng; Xiabin Jing; Zhigang Xie
Journal:  ACS Med Chem Lett       Date:  2015-02-11       Impact factor: 4.345

2.  Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.

Authors:  Wilma Neumann; Brenda C Crews; Menyhárt B Sárosi; Cristina M Daniel; Kebreab Ghebreselasie; Matthias S Scholz; Lawrence J Marnett; Evamarie Hey-Hawkins
Journal:  ChemMedChem       Date:  2014-10-15       Impact factor: 3.466

3.  A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity.

Authors:  Jingjie Tan; Chan Li; Qian Wang; Shuyi Li; Shizhu Chen; Jinchao Zhang; Paul C Wang; Lei Ren; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2018-03-14       Impact factor: 4.939

Review 4.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

5.  Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells.

Authors:  Xu Li; Cuixia Gao; Yupei Wu; C-Yan Cheng; Weiliang Xia; Zhiping Zhang
Journal:  J Mater Chem B       Date:  2015-01-02       Impact factor: 6.331

6.  Novel hybrids derived from aspirin and chalcones potently suppress colorectal cancer in vitro and in vivo.

Authors:  Shan Lu; Obinna N Obianom; Yong Ai
Journal:  Medchemcomm       Date:  2018-08-27       Impact factor: 3.597

7.  An N-Acetyl Cysteine Ruthenium Tricarbonyl Conjugate Enables Simultaneous Release of CO and Ablation of Reactive Oxygen Species.

Authors:  João D Seixas; Miguel Chaves-Ferreira; Diana Montes-Grajales; Ana M Gonçalves; Ana R Marques; Lígia M Saraiva; Jesus Olivero-Verbel; Carlos C Romão; Gonçalo J L Bernardes
Journal:  Chemistry       Date:  2015-08-28       Impact factor: 5.236

8.  Influence of the Number of Axial Bexarotene Ligands on the Cytotoxicity of Pt(IV) Analogs of Oxaliplatin.

Authors:  Yulia N Nosova; Ilia V Zenin; Varvara P Maximova; Ekaterina M Zhidkova; Kirill I Kirsanov; Ekaterina A Lesovaya; Anna A Lobas; Mikhail V Gorshkov; Olga N Kovaleva; Elena R Milaeva; Markus Galanski; Bernhard K Keppler; Alexey A Nazarov
Journal:  Bioinorg Chem Appl       Date:  2017-07-19       Impact factor: 7.778

9.  Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance.

Authors:  Emanuele Petruzzella; Roman Sirota; Irene Solazzo; Valentina Gandin; Dan Gibson
Journal:  Chem Sci       Date:  2018-04-24       Impact factor: 9.825

10.  Leucine aminopeptidase may contribute to the intrinsic resistance of cancer cells toward cisplatin as revealed by an ultrasensitive fluorescent probe.

Authors:  Qiuyu Gong; Wen Shi; Lihong Li; Huimin Ma
Journal:  Chem Sci       Date:  2015-10-22       Impact factor: 9.825
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.